ABT

Abbott Laboratories

ABT.US abbott.com + Research + Basket
CIK 0000001800
Employees 122,000
Phone 224 667 6100
Fiscal year end December
IPO Jan 13, 1978
Address 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
113.60
-1.91 (-1.65%)
USD · NYSE
52-week range
80.89
128.83
Trading at 68% of the 52-week range
Market Cap
199.88B
P/E Ratio
42.94
Forward P/E
18.42
Book Value
29.54
Div. Yield
2.30%
% Institutions
81.90%
% Insiders
0.492%

1 Year

-6.5%

3 Year

+27.4%

10 Year

+244.0%
Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Actions

Add an action for ABT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Robert B. Ford Executive Chairman & CEO 1974
Mr. Philip P. Boudreau CFO & Executive VP of Finance 1973
Mr. Daniel Gesua Sive Salvadori Executive VP and Group President of Established Pharmaceuticals & Nutritional Products 1979
Mr. Christopher J. Scoggins Executive Vice President of Diabetes Care 1970
Ms. Lisa D. Earnhardt Executive VP & Group President of Medical Devices 1970
Ms. Sabina Ewing Senior VP of Business & Technology Services and Chief Information Officer 1974
Mr. Michael Comilla Vice President of Investor Relations. NA
Erica L. Battaglia VP and Chief Ethics & Compliance Officer NA
Ms. Elizabeth C. Cushman Executive VP, General Counsel & Secretary 1970
Ms. Melissa Brotz Senior Vice President of Global Marketing & External Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 30, 2026 Ro Khanna N/A Sale N/A $101.85 N/A —
Mar 24, 2026 Laura Friedman N/A Sale N/A $104.10 N/A —
Mar 23, 2026 Ro Khanna N/A Purchase N/A $104.87 N/A —
Mar 19, 2026 Richard McCormick N/A Purchase N/A $107.16 N/A —
Mar 10, 2026 Ro Khanna N/A Purchase N/A $110.60 N/A —
Mar 02, 2026 Daniel Gesua Sive Salvadori N/A Sale 885.00 $115.58 $102.29K SEC
Mar 02, 2026 Elizabeth C Cushman N/A Sale 263.00 $115.58 $30.40K SEC
Mar 02, 2026 Eric Shroff N/A Sale 709.00 $115.58 $81.95K SEC
Mar 02, 2026 John A Jr. Mccoy N/A Sale 585.00 $115.58 $67.61K SEC
Mar 02, 2026 Mary K Moreland N/A Sale 613.00 $115.58 $70.85K SEC
Feb 27, 2026 Michael T. McCaul N/A Sale N/A $116.17 N/A —
Feb 24, 2026 Ro Khanna N/A Purchase N/A $114.65 N/A —
Feb 18, 2026 Ro Khanna N/A Sale N/A $113.32 N/A —
Feb 17, 2026 Ro Khanna N/A Sale N/A $112.27 N/A —
Feb 10, 2026 Gilbert Ray Cisneros, Jr. N/A Sale N/A $112.23 N/A —
Feb 05, 2026 Michael T. McCaul N/A Purchase N/A $109.03 N/A —
Feb 04, 2026 Daniel J Starks N/A Purchase 10.00K $108.73 $1.09M SEC
Jan 29, 2026 Ro Khanna N/A Sale N/A $106.03 N/A —
Jan 29, 2026 Thomas H. Kean, Jr. N/A Purchase N/A $106.03 N/A —
Jan 23, 2026 Ro Khanna N/A Sale N/A $107.46 N/A —

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 152.56M Jun 30, 2026 8.82% $0.21 4.72%
Vanguard Capital Management, LLC 113.75M Jun 30, 2026 6.57% $0.22 0.71%
State Street Corp 80.93M Jun 30, 2026 4.68% $0.22 1.70%
Charles Schwab Investment Management Inc 59.67M Jun 30, 2026 3.45% $0.72 31.15%
Vanguard Portfolio Management, LLC 49.02M Jun 30, 2026 2.83% $0.20 2.24%
Geode Capital Management, LLC 39.22M Jun 30, 2026 2.27% $0.19 0.18%
Capital Research Global Investors 36.91M Jun 30, 2026 2.13% $0.47 -25.85%
Capital Research & Mgmt Co - Division 3 34.65M Jun 30, 2026 2.00% $0.65 -7.58%
Morgan Stanley - Brokerage Accounts 26.61M Jun 30, 2026 1.54% $0.13 -11.60%
NORGES BANK 23.35M Jun 30, 2026 1.35% $0.21 -0.43%
T. Rowe Price Associates, Inc. 22.79M Jun 30, 2026 1.32% $0.21 31.89%
Franklin Templeton Inc 18.81M Jun 30, 2026 1.09% $0.37 -6.07%
Northern Trust Corp 18.27M Jun 30, 2026 1.06% $0.19 -5.78%
Bank of America Corp 17.67M Jun 30, 2026 1.02% $0.10 -8.34%
The Goldman Sachs Group Inc 16.76M Jun 30, 2026 0.97% $0.13 15.55%
Deutsche Bank AG 16.71M Jun 30, 2026 0.97% $0.44 18.56%
Wells Fargo & Co 15.18M Jun 30, 2026 0.88% $0.22 -4.60%
JPMorgan Chase & Co 15.10M Jun 30, 2026 0.87% $0.08 -43.60%
State Farm Mutual Automobile Ins Co 13.59M Jun 30, 2026 0.79% $0.84 0.00%
FMR Inc 13.42M Jun 30, 2026 0.78% $0.05 23.77%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 54.93M 3.17% ▼ 0.78% Sep 30, 2026
2 Vanguard 500 Index Investor 45.44M 2.63% ▼ 1.80% Sep 30, 2026
3 Schwab US Dividend Equity ETF™ 42.50M 2.46% ▲ 0.17% Oct 30, 2026
4 iShares Core S&P 500 ETF 23.02M 1.33% ▲ 0.26% Oct 23, 2026
5 Fidelity 500 Index 22.61M 1.31% ▲ 0.39% Aug 31, 2026
6 State Street® SPDR® S&P 500® ETF 21.15M 1.22% ▲ 0.17% Oct 29, 2026
7 American Funds Washington Mutual A 17.53M 1.01% ▼ 2.05% Sep 30, 2026
8 Vanguard MStar Value Index Investor 16.48M 0.95% ▼ 1.01% Sep 30, 2026
9 State Street®HlthCrSelSectSPDR®ETF 12.55M 0.73% ▼ 0.02% Oct 29, 2026
10 American Funds Invmt Co of Amer A 10.97M 0.63% ▲ 6.21% Sep 30, 2026

Financial Highlights

▼
Market Cap: $199.88B
EBITDA: $11.95B
P/E Ratio: $42.94
PEG Ratio: $1.56
Book Value: $29.54
Dividend/Share: $2.52
Dividend Yield: 2.30%
Earnings/Share: $2.69
Profit Margin: 9.75%
Operating Margin: 11.34%
ROA (TTM): 5.33%
ROE (TTM): 10.58%
Revenue (TTM): $48.23B
Revenue/Share (TTM): $27.77
Earnings Growth (YOY): -43.70%
Revenue Growth (YOY): 14.50%

Valuation Metrics

Enterprise Value: $216.31B
Trailing P/E: 42.94
Forward P/E: 18.42

Shares Statistics

Shares Outstanding: 1.73B
Shares Float: 1.72B
% Insiders: 0.492%
% Institutions: 81.90%
Shares Short: 17.39M
Shares Short (Prior Month): 19.91M
Short Ratio: 1.84
Short % Float: 1.12%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$44.33B
Cost of Goods Sold
adjust
$-19.72B
Gross Profit
subtotal
$24.61B
SG&A
adjust
$-12.38B
R&D
adjust
$-2.96B
Other Operating Expense
adjust
$-1.25B
Operating Income
subtotal
$8.05B
Other / Non-Operating Items
adjust
$-1.52B
Net Income
subtotal
$6.52B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABT.US!